CUE vs JANX
CUE: Cue Biopharma engineers injectable biologics that selectively modulate disease-specific T cells to restore immune tolerance in autoimmune diseases and activate anti-tumor immunity in cancer. JANX: Janux Therapeutics is a clinical-stage biotech developing next-generation, tumor-activated bispecific immunotherapies to improve the safety and efficacy of cancer and autoimmune treatments.
Side-by-side fundamentals
| Metric | CUE | JANX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $34.20 | $15.62 | |
| Market cap as of 2026-07-23 | $144M | $953M | |
| PEG as of 2026-07-23 | n/a | -0.25 | |
| Net margin as of 2026-07-23 | -59.6% | -354.4% | CUE higher |
| Operating margin as of 2026-07-23 | -59.9% | -505.8% | CUE higher |
| ROE as of 2026-07-23 | -98.3% | -11.8% | JANX higher |
| ROA as of 2026-07-23 | -53.7% | -11.2% | JANX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +309.6% | +47.1% | CUE higher |
| Revenue CAGR (3y) SEC XBRL | +180.5% | n/a | |
| Beta as of 2026-07-23 | 2.49 | 2.53 | |
| 1-year return as of 2026-07-22 close | +26.3% | -37.7% | CUE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.